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Background: We investigated the prognostic significance of tumor regression grade (TRG) after preoperative chemoradia-
tion therapy (preop-CRT) for locally advanced rectal cancer especially in the patients without lymph node metastasis.
Methods: One-hundred seventy-eight patients who had cT3/4 tumors were given 5,040 cGy preoperative radiation with 
5-fluorouracil/leucovorin chemotherapy. A total mesorectal excision was performed 4-6 weeks after preop-CRT. TRG was 
defined as follows: grade 1 as no cancer cells remaining; grade 2 as cancer cells outgrown by fibrosis; grade 3 as a minimal 
presence or absence of regression. The prognostic significance of TRG in comparison with histopathologic staging was 
analyzed.
Results: Seventeen patients (9.6%) showed TRG1. TRG was found to be significantly associated with cancer-specific sur-
vival (CSS; P = 0.001) and local recurrence (P = 0.039) in the univariate study, but not in the multivariate analysis. The 
ypN stage was the strongest prognostic factor in the multivariate analysis. Subgroup analysis revealed TRG to be an inde-
pendent prognostic factor for the CSS of ypN0 patients (P = 0.031). TRG had a stronger impact on the CSS of ypN (-) pa-
tients (P = 0.002) than on that of ypN (+) patients (P = 0.521). In ypT2N0 and ypT3N0, CSS was better for TRG2 than for 
TRG3 (P = 0.041, P = 0.048), and in ypN (-) and TRG2 tumors, CSS was better for ypT1-2 than for ypT3-4 (P = 0.034).
Conclusion: TRG was found to be the strongest prognostic factor in patients without lymph node metastasis (ypN0), and 
different survival was observed according to TRG among patients with a specific histopathologic stage. Thus, TRG may 
provide an accurate prediction of prognosis and may be used for f tailoring treatment for patients without lymph node 
metastasis.
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Prognosis  
treatment of locally advanced rectal cancer. Tumor response after 
preop-CRT for rectal cancer varies considerably, with some enti-
ties showing a complete absence of viable tumor cells and other 
entities exhibiting a mass of tumor cells with little or no regressive 
change. Recent studies have demonstrated that good response to 
preop-CRT in itself is a favorable prognostic factor [1-4]. There-
fore, an accurate evaluation of tumor response to preop-CRT is 
considered essential for predicting oncologic outcomes and plan-
ning further treatment.
The assessment of histopathologic T and N (ypT and ypN) stages 
remains as the gold standard for evaluating response to preop-CRT 
and predicting prognosis. Histopathologic T and N downstaging 
effects have been recognized as important factors for determining 
long-term prognosis. Histopathologic downstaging of rectal can-
INTRODUCTION
Preoperative chemoradiation therapy (preop-CRT) followed by 
total mesorectal excision (TME) has gained popularity in the 
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cer after chemoradiation is associated with an increased resectabil-
ity and more chance of anal sphincter preservation. It is also asso-
ciated with improved local control and long-term survival [2]. Es-
pecially patients who show pathological complete response (pCR; 
complete absence of tumor cells) after the therapy are found to have 
excellent oncologic outcomes [5-7]. Kim et al. [8] also analyzed 
the oncologic results of 114 patients who received preop-CRT for 
locally advanced rectal cancer. They also observed that pCR was 
related to excellent oncologic outcome and that histopathologic N 
downstaging was the most important prognostic factor. However, 
ypT and ypN stages do not provide any information about post-
irradiation changes in tumors, such as the remaining portion of 
viable cancer cells. For example, patients with small islets of viable 
cancer cells scattered in the subserosa layer showing predominant 
fibrosis are still documented as having a ypT3 tumor, but their prog-
nosis might be different from the prognosis given to patients with 
a poorly responding pT3 tumor in which most of cancer cells re-
main viable (Fig. 1A).
The tumor regression grade (TRG) originally proposed by Man-
dard et al. [9] is assessed by examining the residual neoplastic cells 
and scoring the degree of both cytological and stromal changes, 
including necrosis, eosinophilia and fibrosis in esophageal cancer, 
following preoperative chemoradiation therapy. They showed 
through a multivariate analysis that TRG was a significant prognos-
tic factor for 3-year disease-free survival. Ruo et al. [10] reported 
the oncologic outcomes of 69 patients who had been initially di-
agnosed as having cT3-4/N1 rectal cancers and who had under-
gone preop-CRT. They observed that patients showing high de-
grees of tumor regression tended toward good long-term outcomes. 
Although the TRG designates the histopathologic regression of 
tumors in response to radiation, it does not provide any informa-
tion about nodal metastasis or the depth of tumor invasion (Fig. 
1B). Thus, despite abundant previous research, whether or not the 
extent of primary tumor regression has as significant impact as 
histopathologic downstaging remains inconclusive.
The aim of this study was to investigate the prognostic signifi-
cance of a semi-quantitative grading system for tumor regression 
after preop-CRT. We first performed analyses for all patients and 
then for the subgroup of the patients who had no lymph node me-
tastasis (ypN0). We also investigated whether TRG had any corre-
lation to the presence of metastatic lymph node or to histopatho-
logic T- and N- downstagings, all of which are known to be the 
most powerful prognostic factors. Finally, we investigated whether 
different prognoses were observed among the ypN0 patients with 
different TRGs given a specific ypTN stage or vice versa.
METHODS
Eligibility
Between January 1994 and December 2003, 206 consecutive pa-
tients underwent preop-CRT, followed by surgical resection, for 
the treatment of a carcinoma of the rectum at Severance Hospital, 
Yonsei University Health System. Those patients were confirmed 
as having an adenocarcinoma of the rectum by using a rigid sig-
moidoscopic biopsy and as having a stage T3 or T4 tumor as de-
fined on transrectal ultrasonography (TRUS) and pelvic magnetic 
resonance imaging (MRI), regardless of lymph node metastasis. 
The cN stages were decided on the basis of TRUS, computed to-
mograph (CT), and MRI findings. cN (+) was defined as enlarged 
(≥ 10 mm) or spiculate lymph nodes being seen on any preopera-
tive imaging examinations. Digital rectal examination showed fixed 
mass lesions, and initial radiologic evaluation by pelvic MRI re-
vealed bulky tumors, highly suspicious of an invasion of the me-
sorectal fascia or adjacent organs. Distant metastasis was excluded 
in all cases by chest X-radiography and abdominopelvic CT. Ex-
cluded from the study were 28 patients who had undergone a pal-
liative resection (R2) due to incidentally found distant metastases 
or to unresectable primary tumors determined at the time of op-
eration. A total of 178 consecutive patients who underwent a cu-
rative resection for locally advanced rectal cancer after preop-CRT 
were prospectively observed, and their clinical and histopathologic 
data were collected and analyzed.
Fig. 1. There are two different ways of describing tumors. (A) One is by TNM staging, which cannot differentiate a good responding tumor 
from a poorly responding one; the other is by tumor regression grade (TRG), which can tell the difference. (B) On the contrary, TNM staging 
can gives information about the depth of invasion of the tumor whereas TRG cannot tell the difference. 
CRT, chemoradiation therapy.
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Preoperative chemoradiation
All enrolled patients received preop-CRT. Preoperative radiation 
therapy of 45 Gy/25 fractions was delivered to the pelvis, followed 
by a 5.4 Gy boost to the primary tumor over a period of five weeks 
(1.8 Gy for five days) by using linear accelerators with an energy 
of 10 MV. Chemotherapy was administered concurrently with ra-
diotherapy and consisted of intravenous bolus injection of two 
cycles of 5-fluorouracil (425 mg/m2/day) and leucovorin (20 mg/
m2/day) for five days at both the first and the fifth weeks of radia-
tion therapy. The radiation field was as follows: the upper margin 
was 1.5 cm above the sacral promontory (L5 level), and the lateral 
margin was 1.5 cm lateral from the bony pelvis in order to include 
the pelvic lymph nodes. Postoperative adjuvant systemic chemo-
therapy, consisting of 400-425 mg/m2 of 5-fluorouracil plus 20 
mg/m2 leucovorin for 5 days, was administered every 28 days for 
four cycles in all enrolled patients.
Surgical resection
Surgery was performed 4 to 6 weeks after the completion of chemo-
radiation. The method of operation was a tumor-specific mesorec-
tal excision with pelvic autonomic nerve preservation. A tumor-
specific mesorectal excision is defined as a surgical method in 
which the rectum is transected with the surrounding mesorectum 
enclosed by the rectal proper fascia at 4 cm distal from the lower 
edge of the rectum. Thus, all surgeries were performed using a 
sharp pelvic dissection under direct vision along the plane of the 
rectal proper fascia. A tumor-specific mesorectal excision was 
performed according to each patient’s tumor level. In upper rectal 
cancers, the mesorectum was excised 4 cm distal from the lower 
edge of the tumor. A total mesorectal excision was performed in 
middle and distal rectal cancers.
Histopathologic evaluation
Following surgery, pathologic analyses of the tumor specimens 
were performed. ypT and ypN stages and TRG of all enrolled pa-
tients were documented by two pathologists (JYP and HK) who 
had not been informed of the patients’ clinical information. Irra-
diated cancer and harvested mesorectal lymph nodes were sub-
mitted for microscopic analysis. Hematoxylin-eosin-stained sec-
tions were reviewed, and proximal, distal, and circumferential re-
section margins were evaluated. A careful search of the mesorec-
tum was performed to identify as many lymph nodes as possible. 
In cases where only acellular pools of residual mucin were noted, 
the response was considered to be complete. The resected speci-
mens were staged according to the 6th American Joint Commit-
tee on Cancer (AJCC) TNM staging system [11].
The resected specimens were fixed in 4% formaldehyde over-
night. After a specimen had been opened, the tumourous or fi-
brotic area was identified and described macroscopically. For an 
obvious residual primary tumor, a minimum of four paraffin blocks 
were processed. If no tumor was visible, the whole area suggestive 
of disease was sliced and embedded. The TRG was semiquantita-
tively determined by two pathologists uninformed of the clinical 
or radiologic findings. If there were discrepancies between the pa-
thologists, the worse results were selected. Regressive changes of 
the primary tumors in response to preop-CRT were documented 
as described by Mandard et al. [9] Regressive changes included 
both cytological changes, such as cytoplasmic vacuolization and/
or eosinophilia, nuclear pyknosis, and necrosis, and stromal changes, 
such as fibrosis, with or without inflammatory infiltrate. On the 
basis of these changes, primary tumor regression was grouped 
into three categories as suggested by Rodel et al. [6]: Grade 1 (com-
plete regression) showed an absence of histologically identifiable 
residual cancer, with predominant fibrosis extending through the 
different layers of the rectal wall. Grade 2 (intermediate regression) 
was characterized by an increase in the number of residual cancer 
cells, which was still outgrown by fibrosis. Grade 3 (poor regres-
sion) showed residual cancer outgrowing fibrosis characterized by 
a scant presence or the complete absence of regressive changes and 
by residual cancer cells.
Tumor downstaging was assessed by comparing the pre-CRT 
clinical stage (cT and cN stage) with the postoperative histopatho-
logic stage (ypT and ypN stage). T-downstaging was defined as 
the ypT being lower than cT, and N-downstaging was defined as 
cN (+) converting to ypN0. We simplified the cN stages into cN (-) 
and cN (+) because detailed categorization of cN stages has been 
reported to be related with lower accuracy [12] and may cause 
further bias in determining N-downstaging.
Postoperative follow-up
All patients were closely followed by the surgeons, medical oncol-
ogists, and radiation oncologists in the Colorectal Cancer Clinic 
at our institution. Postoperative follow-ups on all patients were 
conducted every three months for three years. Clinical examina-
tion, measurement of serum carcinoembryonic antigen (CEA) 
levels, and chest X-rays were performed during each follow-up. 
After three years, patients underwent follow-up examinations ev-
ery six months. Abdominopelvic CT and whole body bone scans 
were taken at the postoperative sixth month for the first time and 
then every year. An additional pelvic MRI was taken when a rou-
tine CT scan failed to discriminate suspicious lesions in the pelvic 
cavity. The mean and the median follow-up periods were 42.9 ± 
28.3 months and 39 months, respectively.
Statistical analysis
We performed analyses on the association of TRG with histopath-
ologic stages, including T- and N- downstagings, and analyzed the 
prognostic factors for survival and recurrence by using univariate 
and multivariate methods. Subgroups classified according to ypT 
and ypN stages and TRG were analyzed to determine the prog-
nostic impact of TRG for each subgroup.
One-way analysis of variance testing was used to compare con-
tinuous variables. When comparing ordinal categorical variables 
with nominal ones, the χ2 test for trend was used, and for the 
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comparison of nominal categories, the ordinary χ2 test was used. 
The distribution of ordered categories was analyzed by using the 
Spearman correlation coefficient test. Cancer-specific survival, 
time to local recurrence and time to systemic recurrence were 
measured from the time of operation. Data from the patients who 
were alive regardless of recurrence or who had died without re-
currence were not considered in the analysis of CSS. The Kaplan-
Meier method was used for the univariate analyses of survival, 
and the log-rank test was used for the evaluation of differences. 
The multivariate analyses were carried out by using the Cox-pro-
portional hazards model. A two-sided P value of less than 0.05 
was considered significant. An adjustment for multiple testing 
was performed with the Bonferroni method. All statistical tests 
were performed using SPSS ver. 12.0 (SPSS Inc., Chicago, IL, 
USA).
RESULTS
Patient characteristics and the correlation of TRG with 
clinical parameters
Patient characteristics are summarized in Table 1. Patients with 
complete regression of their primary tumors (TRG1) had a signif-
icantly younger mean age than the other TRG groups (P = 0.006). 
The initially small tumors showed a significant tendency to show 
better response to preop-CRT (P = 0.001). Other clinical parame-
ters, such as gender, histology, resection margin involvement, lym-
Table 1. Patients’ characteristics
Characteristics Value
Mean age (yr, range) 54.3 ± 12.0 (26-81)
Male-to-female ratio 121:57
Serum CEA level (ng/mL)
   Initial 29.39 ± 16.30
   Post-op. 7th day   7.27 ± 29.32
cT stage 
   cT3 146 (82.0)
   cT4   32 (18.0)
cN stage
   cN (-)   59 (33.1)
   cN (+) 119 (66.9)
Histology
   Well/moderately differentiated 119 (66.9)
   Poorly differentiated/mucinous   59 (33.1)
Resection margin involvement
   Distal   5 (2.8) 
   Circumferential   19 (10.7)
Presence of lymphovascular invasion   34 (19.1)
Type of operation
   Abdominoperineal resection   57 (32.0)
   Sphincter-saving procedures 121 (68.0)
Tumor regression grade 
   TRG1 (complete response, ypT0) 17 (9.6)
   TRG2 (intermediate response)   68 (38.2)
   TRG3 (poor response)   93 (52.2)
Values are presented as number (%) unless otherwise indicated.
CEA, carcinoembryonic antigen; TRG, total regression grade.
Table 2. Correlations of total regression grade (TRG) with histopath-
ologic stage
Histopathologic stage TRG 1  TRG 2 TRG 3 P-value
ypTa <0.001b
   ypT0    17 (100)      0 (0)      0 (0)
   ypT1  0 (0)   1 (20.0)   4 (80.0)
   ypT2  0 (0) 14 (53.8) 12 (46.2)
   ypT3  0 (0) 49 (41.2) 70 (58.8)
   ypT4  0 (0)   4 (36.4)   7 (63.6)
ypN 0.011b
   ypN0     15 (13.7) 37 (38.9) 45 (47.4)
   ypN1     1 (2.0) 22 (44.9) 26 (53.1)
   ypN2     1 (8.8)   9 (26.5) 22 (64.7)
T-downstaginga 0.326
   (+)     17 (27.4) 21 (33.9) 24 (38.7)
   (-)  0 (0) 47 (40.5) 69 (59.5)
N-downstaging 0.007
   (+)     12 (17.1) 29 (41.4) 29 (41.4)
   (-)     5 (4.6) 39 (36.1) 64 (59.3)
Values are presented as number (%).
aTRG1 was excluded from the analyses; bSpearman’s rho test was used.
Table 3. Five-year CSS, LR, and SR rates according to TNM stage and 
TRG
CSS LR SR 
TNM stage 
   0 100.0  0.0  0.0
   I  82.3 11.5  4.3
   II  64.2 16.5 18.9
   III  53.1 18.1 42.7
TRG
   1  93.3  0.0  6.7
   2  59.1 15.4 23.6
   3  41.8 22.3 33.0
Values are presented as percent.
CSS, cancer-specific survival; LR, local recurrence; SR, systemic recurrence; TNM, 
tumor, node, metastasis; TRG, total regression grade.
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phovascular invasion, serum CEA levels, initial (before preop-CRT) 
clinical T and N stages, tumor location, and sphincter preserva-
tion, were not related to TRG.
Correlation of TRG with histopathologic stages
Given the facts that TRG1 was ypT0 and that ypT0 means T-down-
staging (+) by definition, the assessment of the relationship of TRG 
with ypT stage and T-downstaging was performed excluding the 
TRG1 group. Although advanced ypT stages were noted frequently 
in the group of patients with TRG3 compared to the groups of pa-
tients with TRG2 (r = 0.384; P < 0.001), T-downstaging was found 
not to be related to TRG (P = 0.326) (Table 2). TRG was found to 
have significant correlations with both the ypN stage (P = 0.011) 
and histopathologic N-downstaging (P = 0.007). Two out of 17 
patients (11.7%) with TRG1 showed lymph node metastasis. 
Table 4. Univariate analysis of prognostic factors
Cancer-specific survival Local recurrence Systemic recurrence
5-yr  
cumulative rate 
P-value
5-yr  
cumulative rate
P-value
5-yr  
cumulative rate
P-value
ypN <0.001 <0.001 <0.001
   pN (-) 76.1 10.3 12.5
   pN (+) 47.7 22.8 32.3
ypT <0.001   0.040 0.004
   pT 0-2 88.1 5.1 7.5
   pT 3-4 55.0 23.3 26.8
TRG    0.001  0.039   0.194
   1 93.3 0.0 6.7
   2-3 67.0 9.6 18.6
   4-5 55.9 21.9 26.0
Age   0.525  0.007 0.955
   <55 60.2 24.6 23.3
   ≥55 65.4 7.3 20.0
Gender   0.647   0.908   0.319
   Male 65.0 17.7 19.7
   Female 59.4 20.2 25.1
Operation   0.031   0.003   0.110
   APR 52.0 25.9 31.1
   SPP 68.4 9.8 27.5
Location   0.409   0.085   0.072
   Upper 55.5 22.5 33.2
   Mid 72.4 8.9 24.3
   Low 59.8 24.0 21.6
CEA  <0.001   0.022  0.019 
   ≤5a 69.8 11.4 18.6
   >5 45.7 27.9 31.2
Postop  <0.001   0.008  0.297 
   ≤5 70.2 13.7 30.5
   >5 18.2 40.0 36.8
T-downstage   <0.001   0.285   0.006
   (-) 55.0 15.3 29.7
   (+) 82.2 7.4 11.8
(continued to the next page)
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Prognostic significance of TRG for the whole and the 
subgroup of ypN0 patients
The 5-year cumulative rates of CSS, local recurrences (LR), and 
systemic recurrences (SR) according to histopathologic stages and 
TRG are summarized in Table 3. During the follow-up period, lo-
cal recurrence was observed in 26 patients (14.6%), systemic re-
currence in 30 patients (16.9%) and simultaneous local and sys-
temic recurrence in five patients (2.8%). 
At first, univariate and multivariate analyses of prognostic factors 
were performed for all patients. The univariate analysis revealed 
that TRG was significantly correlated with CSS (P = 0.001) and 
LR (P = 0.039). TRG was found not to be associated with SR. The 
ypT and the ypN stages were significantly associated with CSS (P < 
0.001, P < 0.001), LR (P = 0.040, P < 0.001), and SR (P < 0.001, P 
= 0.004). Histopathologic T-downstaging was found to be associ-
ated with CSS (P < 0.001) and SR (P = 0.006), and N-downstaging 
was significantly associated with CSS (P = 0.018) and LR (P = 0.022) 
(Table 4). Of those histopathologic variables and TRG, the ypN 
stage was found by multivariate analysis to be the strongest inde-
pendent prognostic factor for all three endpoints (for CSS: P = 
0.007, HR = 2.867, 95% CI, 1.325 to 6.202; for LR: P = 0.002, HR = 
11.111, 95% CI, 2.433 to 50.613; for SR: P = 0.003, HR = 3.131, 
95% CI, 1.474 to 6.651) (Table 5).
We performed univariate and multivariate analyses for the sub-
group of the patients without lymph node metastasis (ypN0). Al-
though univariate analyses showed that ypT stage (P = 0.002) and 
TRG (P < 0.001) were both significantly associated with CSS (Ta-
ble 6), on the multivariate analysis, only TRG was found to be an 
independent prognostic factor for CSS of the patients with ypN0 
rectal cancer (P = 0.031) (Table 7).
Survival analyses given a specific TRG and histopathologic stage
When the patients were split into ypN0 and ypN1-2 groups, TRG 
classification correlated significantly only with the CSS of patients 
with ypN0 tumors (P = 0.002) (Fig. 2). Thus, further analysis was 
focused on the CSS of patients with ypN0 tumors. When given a 
specific ypT stage (i.e., ypT2 or ypT3), the CSS of the patients was 
found to be significantly different according to TRG (P = 0.041 
Table 5. Multivariate analysis of prognostic factors
Cancer-specific survival Local recurrence Systemic recurrence
OR (95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value
ypN 2.867 (1.325-6.202) 0.007 4.113 (1.158-14.613) 0.029 3.131 (1.474-6.651) 0.003
Circumferential margin involvement 2.861 (1.154-7.094) 0.023 3.445 (1.084-10.945) 0.036
Postoperative serum CEA > 5 ng/mL   8.884 (3.396-23.239) <0.001
OR, odds ratio; CI, confidence interval; CEA, carcinoembryonic antigen. 
Table 4. (continued from the previous page)  Univariate analysis of prognostic factors
Cancer-specific survival Local recurrence Systemic recurrence
5-yr  
cumulative rate 
P-value
5-yr  
cumulative rate
P-value
5-yr  
cumulative rate
P-value
N-downstage 0.018  0.022  0.173
   (-) 56.6 19.0 25.9
   (+) 75.5 2.1 20.2
CRM   <0.001  <0.001  0.285
   (-) 68.6 11.0 20.2
   (+) 21.1 59.4 25.7
LVI  0.804   0.005  0.206
   (-) 64.0 26.5 20.6
   (+) 61.9 55.8 28.7
Histologic type  0.048  0.004  0.604
   WD 46.7 16.7 25.2
   MD 66.6 13.6 29.5
   PD 54.9 26.4 27.6
TRG, tumor regression grade; APR, abdominoperineal resection; SPP, sphincter-preserving procedures; CEA, carcinoembryonic antigen; CRM, circumferential resection 
margin; LVI, lymphovascular invasion; WD, well-differentiated adenocarcinoma; MD, moderately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma. 
aSerum CEA level of 5 ng/mL was the reference value. 
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Fig. 2. Cancer-specific survival of patients (A) with node-negative and (B) with node-positive tumors according to tumor regression grade 
(TRG). Percents in parentheses are five-year cancer-specific survival rates.
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the patients was significantly different according to ypT stage (P = 
0.047 for TRG2, Fig. 4A; and P = 0.035 for TRG3, Fig. 4B). How-
ever, in patients with ypN1-2 tumors, no similar significant asso-
ciation was found according to TRG or ypT stage.
DISCUSSION
Tumor response to preop-CRT spans a wide spectrum from the 
complete absence of viable cancer cells to no regression at all. In 
those who show favorable tumor responses, a higher rate of cura-
tive resection and a better chance to preserve adjacent pelvic or-
gans and the anal sphincter are expected. Ultimately a higher local 
control rate and a higher disease-free survival rate are achieved. 
Previous studies reported that following preoperative CRT, respect-
ability of over 80% was achieved, and complete pathologic response 
was observed in 10-20% [13-15].
For tumor response to preop-CRT, numerous factors are known 
to be influential [5, 16-18]. In the current study, these treatment-
related factors, such as radiation dosage, use of chemotherapy, and 
interval between preop-CRT and surgery, were relatively homog-
enously controlled. However, the oncologic outcomes reported in 
the present study were poorer than those in previously published 
reports [19-21]. The interval between preop-CRT and surgery was 
relatively short (4-6 weeks in this study), and that might have in-
fluenced the outcomes. A long interval (6-8 weeks) between preop-
Table 6. Univariate analysis of prognostic factors for the cancer-spe-
cific survival rates of patients without lymph node metastasis (ypN0)
Cancer-specific survival
5-yr  
cumulative rate
P-value
ypT stage  0.002
   ypT0-2 88.9
   ypT3-4 69.8
Tumor regression grade  <0.001
   1 100
   2 83.7
   3 64.3
T-downstaging  <0.001
   (-) 55.0
   (+) 82.2
Lymphovascular invasion  0.179
   (-) 78.5
   (+) 80.0
Histological type  0.717
   WD 75.0
   MD 72.3
   PD 50.0
   muc 66.7
Location  0.712
   Upper 83.2
   Mid 78.3
   Low 65.3
TRG, tumor regression grade; WD, well-differentiated adenocarcinoma; MD, mo-
derately differentiated adenocarcinoma; PD, poorly differentiated adenocarcinoma; 
muc: mucinous adenocarcinoma including a signet ring cell carcinoma.
Table 7. Multivariate analysis of prognostic factors for the cancer-spe-
cific survival rates of patients without lymph node metastasis (ypN0)
Variable P-value Odds ratio
95% Confidence 
interval
ypT0-2 against ypT3-4 0.134 0.252 0.042 to 1.527
TRG 0.031
   TRG 2 against TRG 3 0.943 0.000 0.000 to 2.01 × e167
   TRG 1 against TRG 3 0.008 0.088 0.014 to 0.537
T downstage 0.449 0.578 0.140 to 2.387
TRG, tumor regression grade.
for ypT2 (Fig. 3A) and P = 0.048 for ypT3 (Fig. 3B). On the other 
hand, when given a specific TRG (i.e., TRG2 or TRG3), the CSS of 
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Fig. 3. Cancer-specific survival (CSS) of patients with ypT2-3/N0 according to tumor regression grade (TRG): (A) CSS of patients with ypT2N0 
tumors according to TRG and (B) that of patients with ypT3N0 tumors according to TRG. Percents in parentheses are five-year cancer-specific 
survival rates.
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Fig. 4. Cancer-specific survival (CSS) of patients having TRG2 and ypN0 tumors according to ypT stage: (A) CSS of patients with TRG2 ypN0 
tumors according to ypT stage and (B) that of patients with TRG3 ypN0 tumors according to ypT stage. Percents in parentheses are five-year 
cancer-specific survival rates.
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CRT and surgery is known to be related with better tumor response 
and higher downstaging [18]. However, pCR rates were not found 
to be different in regard to the interval. Moreover, according to 
the report on long-term oncologic outcomes in the Lyon R09-1 
trial, the interval was not found to be related to survival and local 
recurrence [22]. Thus, the poorer outcomes of the current study 
are more likely due to the advanced stages of the enrolled patients. 
We enrolled patients who showed fixed tumors on digital rectal 
examination and circumferential-margin-threatening or meso-
rectal-fascia-involving tumors on pelvic MRI.
Although tumor regression grade basically scores the ratio of re-
sidual cancer cell to radiation-induced fibrosis, a standard method 
for scoring tumor regression grade still does not exist. This is im-
portant because documentation of TRG can be different depend-
ing on the methods used to prepare slides, the number of slides 
reviewed per tumor, the experience of the reviewers, and so on. 
Mandard et al. [9] and other researchers [10, 23] advocated five-
point grading systems while others [6, 7] advocated three-point 
systems. Ryan et al. [24] compared the five-point TRG and the 
three-point grade system with respect to tumor response after pre-
operative CRT for rectal cancer and evaluated both for intra- and 
inter-observer variability. They concluded that although prognos-
tic impact might be the same, the three-point TRG was better with 
respect to intra- and inter-observer agreement. The three-point 
grade has the advantage of better reproducibility, with similar prog-
nostic significance. Thus, we used the three-point grading system 
suggested by Rodel et al. [6].
Despite all the controversies, few studies performed subgroup 
analyses to shed light on the prognostic impact of TRG for specific 
group of the patients. As a whole, TRG has been uniformly found 
by univariate analysis to have a prognostic value for survival and 
recurrence in rectal cancer after irradiation [1, 3, 4, 6, 10, 25, 26]. 
Most series, however, have failed to establish TRG as an indepen-
dent prognostic factor stronger than ypT or ypN [3, 4, 6, 10]. These 
results might indicate that the prognostic value of TRG was ad-
versely impacted by stronger factors such as histopathologic N 
stage. In a large prospective series, Rodel et al. [6] found that in 
the analysis of a subgroup of patients with ypN0 tumors, the five-
year DFS for patients with ypT3-4, ypN0 tumors showing inter-
mediate tumor regression was superior to that for those showing 
poor regression. We demonstrated that for ypN0 patients, TRG 
was the most powerful prognostic factor, and this result supports 
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that the finding of Rodel et al. [6]. On the basis of these results, we 
can assume that TRG has weak prognostic value in patients with 
lymph node metastasis, but that it has stronger prognostic value 
in patients without lymph node metastasis.
Wheeler et al. [7] postulated that although cancer invasion into 
the bowel wall progressed in a stepwise fashion, radiation therapy 
did not necessarily reverse those changes, but instead reduced the 
number of viable cancer cells (and normal cells) that were in the 
field of irradiation. They, thus, hypothesized that it would be ap-
propriate to use a pathologic staging system that measured tumor 
regression of an irradiated rectal cancer in addition to the ypT and 
ypN stages because prognosis would differ according to both TRG 
and histopathologic stage. There have been many reports that in-
directly support this hypothesis [3, 4, 6, 7]. In this study, we dem-
onstrated no correlation between T-downstaging and TRG, which 
might reflect the quantitative fashion of tumor regression caused 
by preop-CRT. We found significant correlations of TRG with ypN 
stage and N-downstaging because both criteria are quantitative 
measures of metastatic lymph node involvement. With 4th or older 
versions of AJCC TNM systems, in which N stage was defined ac-
cording to the anatomical location, such correlations might not 
have been found. We also observed different cancer-specific sur-
vivals according to different TRGs among the subgroups of pa-
tients with the same ypT stages. Thus, our conclusions support 
the suggestion by Wheeler et al. [7].
What happens if when we do not know about the lymph node 
status, for example, when a local excision is performed for a shrunk 
rectal cancer after preop-CRT? In that case, the possibility of lymph 
node metastasis should be carefully considered. Because of the 
low accuracy of lymph node evaluation when using conventional 
radiologic techniques, our question will be whether it is possible 
to predict lymph node metastasis based on clinical and histopath-
ologic variables. In accordance with a previous study, our data 
showed a significant correlation of TRG with ypN stage and N-
downstaging. However, our study showed that the percentage of 
patients with metastatic lymph nodes was as high as 11.7% for 
those who had shown complete regression (TRG1). We also ob-
served that TRG1 (complete regression) and TRG2 (intermediate 
regression) showed a significant difference in the incidence of 
lymph node metastasis. According to Kim et al. [27], only com-
plete regression was associated with a low incidence of lymph node 
metastasis, and a sharp demarcation existed between complete re-
gression (2.2%) and nearly complete regression (16.1%). More re-
cently, Caricato et al. [28] reported tumor regression in mesorec-
tal lymph nodes of 35 rectal cancer patients treated with preoper-
ative chemoradiation. They found an excellent correlation between 
lymph node regression grade and primary tumor regression grade; 
they also observed a sharp demarcation (11.7% vs. 45.6%) between 
complete regression and intermediate regression. Upon the basis 
of those results, we conclude that a good TRG still has a relatively 
high risk of lymph node metastasis and that although a correlation 
might exist between the responses of primary tumors and lymph 
node metastases, TRG is not an indicator for the response of lymph 
nodes, but is an indicator for the response of the primary tumor. 
Additionally, in contrast to previous literature [4, 25], our current 
recommendation is to perform standard radical surgery regard-
less of tumor response.
In this study, long-term oncologic outcomes in patients with rec-
tal cancer who had been given preoperative chemoradiation ther-
apy were found to depend on histopathologic T and N downstag-
ing and on tumor regression grade. However, TRG alone may not 
be enough to give a prognosis. Thus, traditional histopathologic 
staging, especially N stage, remains the most important prognos-
tic factor for cancer-specific survival, and TRG may aid in form-
ing a prognosis for patients, particularly those without lymph node 
metastasis. In patients who achieved N-downstaging after preop-
erative chemoradiation, an accurate prediction of cancer-specific 
survival requires both information on the number of viable can-
cer cells remaining (TRG) and on whether the foci of viable can-
cer cells are located within or out of the rectal wall (ypT stage). 
Because not many prognostic factors are known for the patients 
without lymph node metastasis, the results of this study can be use-
fully applied to clinical practice. 
According to the results from the current study, TRG following 
preop-CRT was found to have a limited prognostic significance 
for the treatment of locally advanced rectal cancer. Although as a 
whole TRG had a weaker prognostic power than ypN stage, it was 
found to have the strongest prognostic power in patients without 
lymph node metastasis. For better prediction of oncologic out-
comes after preoperative chemoradiation therapy in locally ad-
vanced rectal cancer, tumor regression grade should be addressed 
in addition to the ypT and ypN staging system.
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